Domo signs strategic collaboration agreement with AWS for AI solutions
Investing.com - H.C. Wainwright has reiterated its Buy rating and $8.00 price target on Gain Therapeutics (NASDAQ:GANX), maintaining its positive outlook on the clinical-stage biotechnology company. Currently trading at $1.97, GANX has shown strong momentum with an 11.3% gain over the past week. According to InvestingPro data, analyst targets range from $5 to $12, suggesting significant upside potential.
The Phase 1b clinical study evaluating GT-02287, Gain’s lead allosteric small molecule asset, in Parkinson’s disease patients with or without a GBA1 mutation reached its original enrollment target of 16 participants at the end of June, ahead of schedule. Enrollment remained open to pre-screened candidates meeting study criteria through July 31, with total participation not expected to exceed 20 individuals. With a market capitalization of $68.1 million, GANX maintains a strong balance sheet, holding more cash than debt - a crucial factor for clinical-stage biotech companies.
Gain Therapeutics has submitted a request to extend the dosing duration of the Phase 1b study beyond the current 90-day protocol limit, with an update on this request expected in the coming weeks. The company plans to provide complete results on 90-day biomarker evidence from all cerebrospinal fluid (CSF) and blood samples during the fourth quarter of 2025.
The biomarker readout will be significant as it may clarify GT-02287’s mechanism of action, potentially demonstrating effects beyond activation of lysosomal GCase. Secondary endpoints include pharmacokinetics, GCase modulation, levels of GCase substrates, and other biomarkers in both plasma and CSF.
The company believes extending the Phase 1b study will better inform Phase 2 protocol design and planning, which is scheduled for early 2026. For deeper insights into GANX’s financial health and growth prospects, including exclusive biotech sector analysis tools and detailed Fair Value calculations, visit InvestingPro, where you’ll find comprehensive research reports covering 1,400+ US stocks.
In other recent news, Gain Therapeutics has been actively progressing in several areas. The company announced accelerated enrollment in its Phase 1b clinical study for GT-02287, aimed at treating Parkinson’s disease, with 16 participants enrolled by the end of June. This exceeded their original timeline, allowing for an earlier analysis of cerebrospinal fluid samples by the fourth quarter of 2025. Meanwhile, Gain Therapeutics has also amended its certificate of incorporation to increase the number of authorized common shares from 50 million to 100 million, following a stockholder vote. Additionally, the company plans to release cerebrospinal fluid data on key biomarkers in the fourth quarter of this year. However, BTIG has lowered its price target for Gain Therapeutics to $9.00, maintaining a Buy rating, as the company continues its clinical trials. Gain Therapeutics also announced a public offering of common stock and warrants, intending to use the proceeds for the development of its lead product candidate, GT-02287, and for general corporate purposes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.